|
1
|
Mok TS, Wu YL, Thongprasert S, Yang CH,
Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, et
al: Gefitinib or carboplatin-paclitaxel in pulmonary
adenocarcinoma. N Engl J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Maemondo M, Inoue A, Kobayashi K, Sugawara
S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I,
et al: Gefitinib or chemotherapy for non-small-cell lung cancer
with mutated EGFR. N Engl J Med. 362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mitsudomi T, Morita S, Yatabe Y, Negoro S,
Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, et
al: Gefitinib versus cisplatin plus docetaxel in patients with
non-small-cell lung cancer harbouring mutations of the epidermal
growth factor receptor (WJTOG3405): An open label, randomised phase
3 trial. Lancet Oncol. 11:121–128. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kobayashi S, Boggon TJ, Dayaram T, Jänne
PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG and Halmos
B: EGFR mutation and resistance of non-small-cell lung cancer to
gefitinib. N Engl J Med. 352:786–792. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Maheswaran S, Sequist LV, Nagrath S, Ulkus
L, Brannigan B, Collura CV, Inserra E, Diederichs S, Iafrate AJ,
Bell DW, et al: Detection of mutations in EGFR in circulating
lung-cancer cells. N Engl J Med. 359:366–377. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yu HA, Arcila ME, Rekhtman N, Sima CS,
Zakowski MF, Pao W, Kris MG, Miller VA, Ladanyi M and Riely GJ:
Analysis of tumor specimens at the time of acquired resistance to
EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.
Clin Cancer Res. 19:2240–2247. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jänne PA, Yang JC, Kim DW, Planchard D,
Ohe Y, Ramalingam SS, Ahn MJ, Kim SW, Su WC, Horn L, et al: AZD9291
in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J
Med. 372:1689–1699. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sequist LV, Soria JC, Goldman JW, Wakelee
HA, Gadgeel SM, Varga A, Papadimitrakopoulou V, Solomon BJ, Oxnard
GR, Dziadziuszko R, et al: Rociletinib in EGFR-mutated
non-small-cell lung cancer. N Engl J Med. 372:1700–1709. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Murtaza M, Dawson SJ, Tsui DW, Gale D,
Forshew T, Piskorz AM, Parkinson C, Chin SF, Kingsbury Z, Wong AS,
et al: Non-invasive analysis of acquired resistance to cancer
therapy by sequencing of plasma DNA. Nature. 497:108–112. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Del Re M, Vasile E, Falcone A, Danesi R
and Petrini I: Molecular analysis of cell-free circulating DNA for
the diagnosis of somatic mutations associated with resistance to
tyrosine kinase inhibitors in non-small-cell lung cancer. Expert
Rev Mol Diagn. 14:453–468. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tseng JS, Yang TY, Tsai CR, Chen KC, Hsu
KH, Tsai MH, Yu SL, Su KY, Chen JJ and Chang GC: Dynamic plasma
EGFR mutation status as a predictor of EGFR-TKI efficacy in
patients with EGFR-mutant lung adenocarcinoma. J Thorac Oncol.
10:603–610. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ottesen EA, Hong JW, Quake SR and
Leadbetter JR: Microfluidic digital PCR enables multigene analysis
of individual environmental bacteria. Science. 314:1464–1467. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hindson CM, Chevillet JR, Briggs HA,
Gallichotte EN, Ruf IK, Hindson BJ, Vessella RL and Tewari M:
Absolute quantification by droplet digital PCR versus analog
real-time PCR. Nat Methods. 10:1003–1005. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yung TK, Chan KC, Mok TS, Tong J, To KF
and Lo YM: Single-molecule detection of epidermal growth factor
receptor mutations in plasma by microfluidics digital PCR in
non-small cell lung cancer patients. Clin Cancer Res. 15:2076–2084.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Oxnard GR, Paweletz CP, Kuang Y, Mach SL,
O'Connell A, Messineo MM, Luke JJ, Butaney M, Kirschmeier P,
Jackman DM and Jänne PA: Noninvasive detection of response and
resistance in EGFR-mutant lung cancer using quantitative
next-generation genotyping of cell-free plasma DNA. Clin Cancer
Res. 20:1698–1705. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Watanabe M, Kawaguchi T, Isa S, Ando M,
Tamiya A, Kubo A, Saka H, Takeo S, Adachi H, Tagawa T, et al:
Ultra-sensitive detection of the pretreatment EGFR T790M mutation
in non-small cell lung cancer patients with an EGFR-activating
mutation using droplet digital PCR. Clin Cancer Res. 21:3552–3560.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhu G, Ye X, Dong Z, Lu YC, Sun Y, Liu Y,
McCormack R, Gu Y and Liu X: Highly sensitive droplet digital PCR
method for detection of EGFR activating mutations in plasma
cell-free DNA from patients with advanced non-small cell lung
cancer. J Mol Diagn. 17:265–272. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cha YK, Lee HY, Ahn MJ, Choi YL, Lee JH,
Park K and Lee KS: Survival outcome assessed according to tumor
burden and progression patterns in patients with epidermal growth
factor receptor mutant lung adenocarcinoma undergoing epidermal
growth factor receptor tyrosine kinase inhibitor therapy. Clin Lung
Cancer. 16:228–236. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sorensen BS, Wu L, Wei W, Tsai J, Weber B,
Nexo E and Meldgaard P: Monitoring of epidermal growth factor
receptor tyrosine kinase inhibitor-sensitizing and resistance
mutations in the plasma DNA of patients with advanced non-small
cell lung cancer during treatment with erlotinib. Cancer.
120:3896–3901. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ishii H, Azuma K, Sakai K, Kawahara A,
Yamada K, Tokito T, Okamoto I, Nishio K and Hoshino T: Digital PCR
analysis of plasma cell-free DNA for non-invasive detection of drug
resistance mechanisms in EGFR mutant NSCLC: Correlation with paired
tumor samples. Oncotarget. 6:30850–30858. 2015.PubMed/NCBI
|
|
21
|
Wang Z, Chen R, Wang S, Zhong J, Wu M,
Zhao J, Duan J, Zhuo M, An T, Wang Y, et al: Quantification and
dynamic monitoring of EGFR T790M in plasma cell-free DNA by digital
PCR for prognosis of EGFR-TKI treatment in advanced NSCLC. PLoS
One. 9:e1107802014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kuiper JL, Heideman DA, Thunnissen E, Paul
MA, van Wijk AW, Postmus PE and Smit EF: Incidence of T790M
mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients.
Lung Cancer. 85:19–24. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hata A, Katakami N, Yoshioka H, Takeshita
J, Tanaka K, Nanjo S, Fujita S, Kaji R, Imai Y, Monden K, et al:
Rebiopsy of non-small cell lung cancer patients with acquired
resistance to epidermal growth factor receptor-tyrosine kinase
inhibitor: Comparison between T790M mutation-positive and
mutation-negative populations. Cancer. 119:4325–4332. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Su KY, Chen HY, Li KC, Kuo ML, Yang JC,
Chan WK, Ho BC, Chang GC, Shih JY, Yu SL and Yang PC: Pretreatment
epidermal growth factor receptor (EGFR) T790M mutation predicts
shorter EGFR tyrosine kinase inhibitor response duration in
patients with non-small-cell lung cancer. J Clin Oncol. 30:433–440.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fujita Y, Suda K, Kimura H, Matsumoto K,
Arao T, Nagai T, Saijo N, Yatabe Y, Mitsudomi T and Nishio K:
Highly sensitive detection of EGFR T790M mutation using colony
hybridization predicts favorable prognosis of patients with lung
cancer harboring activating EGFR mutation. J Thorac Oncol.
7:1640–1644. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Watanabe M, Kawaguchi T, Isa SI, Ando M,
Tamiya A, Kubo A, Saka H, Takeo S, Adachi H, Tagawa T, et al:
Ultra-sensitive detection of the pretreatment EGFR T790M mutation
in non-small-cell lung cancer patients with an EGFR-activating
mutation using droplet digital PCR. Clin Cancer Res. 21:3552–3560.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhou Q, Zhang XC, Chen ZH, Yin XL, Yang
JJ, Xu CR, Yan HH, Chen HJ, Su J, Zhong WZ, et al: Relative
abundance of EGFR mutations predicts benefit from gefitinib
treatment for advanced non-small-cell lung cancer. J Clin Oncol.
29:3316–3321. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zheng D, Ye X, Zhang MZ, Sun Y, Wang JY,
Ni J, Zhang HP, Zhang L, Luo J, Zhang J, et al: Plasma EGFR T790M
ctDNA status is associated with clinical outcome in advanced NSCLC
patients with acquired EGFR-TKI resistance. Sci Rep. 6:209132016.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chmielecki J, Foo J, Oxnard GR, Hutchinson
K, Ohashi K, Somwar R, Wang L, Amato KR, Arcila M, Sos ML, et al:
Optimization of dosing for EGFR-mutant non-small cell lung cancer
with evolutionary cancer modeling. Sci Transl Med. 3:90ra59. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Crowley E, Di Nicolantonio F, Loupakis F
and Bardelli A: Liquid biopsy: Monitoring cancer-genetics in the
blood. Nat Rev Clin Oncol. 10:472–484. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Haber DA and Velculescu VE: Blood-based
analyses of cancer: Circulating tumor cells and circulating tumor
DNA. Cancer Discov. 4:650–661. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Park JH, Kim TM, Keam B, Jeon YK, Lee SH,
Kim DW, Chung DH, Kim YT, Kim YW and Heo DS: Tumor burden is
predictive of survival in patients with non-small-cell lung cancer
and with activating epidermal growth factor receptor mutations who
receive gefitinib. Clin Lung Cancer. 14:383–389. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zander T, Scheffler M, Nogova L, Kobe C,
Engel-Riedel W, Hellmich M, Papachristou I, Toepelt K, Draube A,
Heukamp L, et al: Early prediction of nonprogression in advanced
non-small-cell lung cancer treated with erlotinib by using
[(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron
emission tomography. J Clin Oncol. 29:1701–1708. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Mok T, Wu YL, Lee JS, Yu CJ, Sriuranpong
V, Sandoval-Tan J, Ladrera G, Thongprasert S, Srimuninnimit V, Liao
M, et al: Detection and dynamic changes of EGFR mutations from
circulating tumor DNA as a predictor of survival outcomes in NSCLC
patients treated with first-line intercalated erlotinib and
chemotherapy. Clin Cancer Res. 21:3196–3203. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Nishino M, Dahlberg SE, Cardarella S,
Jackman DM, Rabin MS, Ramaiya NH, Hatabu H, Jänne PA and Johnson
BE: Volumetric tumor growth in advanced non-small cell lung cancer
patients with EGFR mutations during EGFR-tyrosine kinase inhibitor
therapy: Developing criteria to continue therapy beyond RECIST
progression. Cancer. 119:3761–3768. 2013. View Article : Google Scholar : PubMed/NCBI
|
